Cancer Family
Infection-Related Malignant Neoplasm
CI-CAN-00000206Explore in graph →
133 active trials4 approved drugs1 evidence items
- NCIt
- C27223
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000206Explore in graph →
Clinical trials
539 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (75)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06454175 | A Phase I Clinical Trial to Evaluate the Safety of 15-valent HPV Vaccine in Healthy Chinese People Aged 18-45 Years | unknown | Phase 1 | 72 | Shanghai Bovax Biotechnology Co., Ltd.INDUSTRY | 1 | Jan 6, 2025 | clinicaltrials |
| NCT05577364 | Selinexor in Combination With R-CHOP Followed by Selinexor Maintenance for Untreated EBV-positive DLBCL Patients | unknown | Phase 1 / Phase 2 | 54 | Sun Yat-sen UniversityOTHER | 1 | Dec 14, 2023 | clinicaltrials |
| NCT03475953 | A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors(REGOMUNE) | unknown | Phase 1 / Phase 2 | 747 | Institut BergoniéOTHER | 1 | Mar 3, 2023 | clinicaltrials |
| NCT05340829 | Evaluate the Safety and Effect of ThisCART19A in Patients With AIDS Related B Cell Lymphoma/Lympholeukemia | unknown | Phase 1 | 18 | He HuangOTHER | 1 | Apr 22, 2022 | clinicaltrials |
| NCT04058470 | Toripalimab Plus Rituximab Followed by R-CHOP for Elderly Patients With Untreated Diffused B Cell Lymphoma | unknown | Phase 1 / Phase 2 | 140 | Huiqiang HuangOTHER | 1 | Apr 14, 2022 | clinicaltrials |
| NCT03226470 | Study of Targeted Therapy Using Transcription Activator-like Effector Nucleases in Cervical Precancerous Lesions | unknown | Phase 1 | 40 | Huazhong University of Science and TechnologyOTHER | 1 | Jan 14, 2022 | clinicaltrials |
| NCT04476459 | Camrelizumab in Combination With Apatinib in Refractory and Relapsed DLBCL | unknown | Phase 1 / Phase 2 | 33 | Huiqiang HuangOTHER | 1 | Mar 15, 2021 | clinicaltrials |
| NCT04796857 | Tislelizumab in Combination With Lenalidomide in Refractory and Relapsed Elderly Patients With Non-GCB DLBCL | unknown | Phase 1 / Phase 2 | 30 | Huiqiang HuangOTHER | 1 | Mar 15, 2021 | clinicaltrials |
| NCT04008394 | Anti-CD30 CAR-T Therapy in Patients With Refractory/Relapsed Lymphocyte Malignancies | unknown | Phase 1 | 50 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Aug 7, 2019 | clinicaltrials |
| NCT02800369 | Study of Molecular-targeted Therapy Using Zinc Finger Nuclease in Cervical Precancerous Lesions | unknown | Phase 1 | 20 | Huazhong University of Science and TechnologyOTHER | 1 | Jul 12, 2017 | clinicaltrials |
| NCT03057912 | A Safety and Efficacy Study of TALEN and CRISPR/Cas9 in the Treatment of HPV-related Cervical Intraepithelial NeoplasiaⅠ | unknown | Phase 1 | 60 | First Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 1 | Jun 9, 2017 | clinicaltrials |
| NCT01823718 | Cell Bank of Epstein Barr Virus Specific Cytotoxic T Lymphocytes | unknown | Phase 1 | 18 | Nantes University HospitalOTHER | 1 | Nov 15, 2013 | clinicaltrials |
Data updated 22 days agoSource updated Jan 6, 2025source: clinicaltrials